GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (CHIX:AMGd) » Definitions » E10

Amgen (CHIX:AMGD) E10 : €11.09 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Amgen E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Amgen's adjusted earnings per share data for the three months ended in Sep. 2024 was €4.703. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €11.09 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Amgen's average E10 Growth Rate was 1.90% per year. During the past 3 years, the average E10 Growth Rate was 10.60% per year. During the past 5 years, the average E10 Growth Rate was 11.10% per year. During the past 10 years, the average E10 Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Amgen was 25.30% per year. The lowest was 6.20% per year. And the median was 16.60% per year.

As of today (2024-12-14), Amgen's current stock price is €264.75. Amgen's E10 for the quarter that ended in Sep. 2024 was €11.09. Amgen's Shiller PE Ratio of today is 23.87.

During the past 13 years, the highest Shiller PE Ratio of Amgen was 36.60. The lowest was 18.58. And the median was 26.48.


Amgen E10 Historical Data

The historical data trend for Amgen's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen E10 Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 10.74

Amgen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.31 10.74 10.87 10.67 11.09

Competitive Comparison of Amgen's E10

For the Drug Manufacturers - General subindustry, Amgen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Shiller PE Ratio falls into.



Amgen E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=4.703/133.0289*133.0289
=4.703

Current CPI (Sep. 2024) = 133.0289.

Amgen Quarterly Data

per share eps CPI Adj_EPS
201412 1.362 99.070 1.829
201503 1.950 99.621 2.604
201506 1.916 100.684 2.532
201509 2.174 100.392 2.881
201512 2.176 99.792 2.901
201603 2.245 100.470 2.973
201606 2.198 101.688 2.875
201609 2.388 101.861 3.119
201612 2.455 101.863 3.206
201703 2.609 102.862 3.374
201706 2.590 103.349 3.334
201709 2.316 104.136 2.959
201712 -4.977 104.011 -6.366
201803 2.636 105.290 3.330
201806 2.979 106.317 3.727
201809 2.451 106.507 3.061
201812 2.646 105.998 3.321
201903 2.814 107.251 3.490
201906 3.159 108.070 3.889
201909 2.969 108.329 3.646
201912 2.565 108.420 3.147
202003 2.778 108.902 3.393
202006 2.708 108.767 3.312
202009 2.912 109.815 3.528
202012 2.269 109.897 2.747
202103 2.377 111.754 2.830
202106 0.672 114.631 0.780
202109 2.814 115.734 3.235
202112 2.974 117.630 3.363
202203 2.433 121.301 2.668
202206 2.318 125.017 2.467
202209 4.020 125.227 4.270
202212 2.832 125.222 3.009
202303 4.932 127.348 5.152
202306 2.372 128.729 2.451
202309 3.017 129.860 3.091
202312 1.302 129.419 1.338
202403 -0.193 131.776 -0.195
202406 1.282 132.554 1.287
202409 4.703 133.029 4.703

Add all the adjusted EPS together and divide 10 will get our e10.


Amgen  (CHIX:AMGd) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Amgen's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=264.75/11.09
=23.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Amgen was 36.60. The lowest was 18.58. And the median was 26.48.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Amgen E10 Related Terms

Thank you for viewing the detailed overview of Amgen's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Headlines

No Headlines